Search - tctmd.com

Displaying 161 - 180 of 295

$The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...$

Presentation TCT 2013

The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...

Presenter: Tahei Ichinohe, Kazushige Kadota, Haruki Eguchi, Seiji Habara, Hiroyuki Tanaka, Takeshi Tada, Yasushi Fuku, Naoki Oka, Hiroyuki Yamamoto, Satoki Fujii, Tsuyoshi Goto, Kazuaki Mitsudo

January 31, 2013

Presentation TCT 2013

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Presenter: Aris Moschovitis, Giulio Stefanini, Michael Magro, Lorenz R?ber, Bindu Kalesan, Masanori Taniwaki, Joost Daemen, Peter Wenaweser, Ron Van Domburg, Bernhard Meier, Peter Juni, Patrick Serruys, Stephan Windecker

January 31, 2013

Presentation TCT 2013

Seven-year Clinical Outcomes of Sirolimus-Eluting Stent Versus Bare-Metal Stent; A Matched Analysis From A Real World, Single Center Registry

Presenter: Jin-Sung Lee, Yoon-Jung Choi, Ung Kim, Jong-Seon Park, Jang-Won Son, Sang-Hee Lee, Dong-Gu Shin, Young-Jo Kim

January 31, 2013

Presentation TCT 2013

NOYA I: A Prospective Randomized Trial of the Biodegradable Polymer NOYA Sirolimus-Eluting Stent Compared with the Durable Polymer FIREBIRD 2 Sirolimus-Eluting Stent in Patients...

Presenter: Bo Xu, Kefei Dou, Yuejin Yang, Shuzheng Lu, Lefeng Wang, Haichang Wang, Zhanquan Li, Lei Wang, YunDai Chen, Yong Huo, Ajay Kirtane, Run-Lin Gao

January 31, 2013

Presentation TCT 2013

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Presenter: Lisbeth Antonsen, Lisette Okkels Jensen, Michael Maeng, Per Thayssen, Evald H?j Christiansen, Knud N?rregaard Hansen, Anne Kaltoft, Henrik Steen Hansen, Leif Thuesen, Jens Flensted Lassen

January 31, 2013

Presentation TCT 2013

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Presenter: Young-Rak Cho, Jung-Min Ahn, Soo-Jin Kang, Young-Hak Kim, Won-Jang Kim, Jong-Young Lee, Woo Seok Lee, Gyung-Min Park, Seung-Jung Park

January 31, 2013

Presentation TCT 2013

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Presenter: Hironori Kitabata, Joshua Loh, Gabriel Sardi, Salem Badr, Danny Dvir, Israel Barbash, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2012

Jason Kahn

January 02, 2013

News Daily News

EES Outperform First-Generation DES in Treatment of CTOs

L.A. McKeown

December 27, 2012

News Daily News

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Presentation TCT 2012

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Presenter: Patrick Serruys

October 23, 2012

Presentation TCT 2012

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

Presenter: Giulio Stefanini

October 23, 2012

Presentation TCT 2012

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Presenter: Run-Lin Gao

October 23, 2012

Advertisement

The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Seven-year Clinical Outcomes of Sirolimus-Eluting Stent Versus Bare-Metal Stent; A Matched Analysis From A Real World, Single Center Registry

NOYA I: A Prospective Randomized Trial of the Biodegradable Polymer NOYA Sirolimus-Eluting Stent Compared with the Durable Polymer FIREBIRD 2 Sirolimus-Eluting Stent in Patients...

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

TCTMD’s Top 10 Most Popular News Stories for 2012

EES Outperform First-Generation DES in Treatment of CTOs

APPOSITION II Published: Self-Expanding Stent Performs Well in STEMI Patients

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content